macroglobulinemia


Also found in: Dictionary, Encyclopedia, Wikipedia.
Related to macroglobulinemia: Waldenstrom's macroglobulinemia

macroglobulinemia

 [mak″ro-glob″u-lin-e´me-ah]
increased levels of macroglobulins in the blood.
Waldenström's macroglobulinemia a type of plasma cell dyscrasia with cells having lymphocytic, plasmacytic, or intermediate morphology and secreting IgM M-component. There is diffuse infiltration of bone marrow and in many cases also of the spleen, liver, or lymph nodes. The circulating macroglobulin produces symptoms of hyperviscosity syndrome: weakness, fatigue, bleeding disorders, and visual disturbances. Peak incidence is in the sixth and seventh decades.

mac·ro·glob·u·lin·e·mi·a

(mak'rō-glob'yū-li-nē'mē-ă),
The presence of increased levels of macroglobulins in the circulating blood.

macroglobulinemia

/mac·ro·glob·u·lin·emia/ (-glob″ūl-in-ēm´e-ah) increased levels of macroglobulins in the blood.
Waldenström's macroglobulinemia  a plasma cell dyscrasia resembling leukemia, with cells of lymphocytic, plasmacytic, or intermediate morphology that secrete an IgM M component, diffuse infiltration of bone marrow, weakness, fatigue, bleeding disorders, and visual disturbances.

macroglobulinemia

(măk′rō-glŏb′yə-lə-nē′mē-ə)
n.
A condition marked by an abnormally high concentration of macroglobulins in the blood serum.

macroglobulinemia

[mak′rōglob′yoo͡linē′mē·ə]
Etymology: Gk, makros + L, globulus, small ball; Gk, haima, blood
plasma presence of a high molecular-weight globulin such as alpha-2-macroglobulin or an immunoglobulin of the IgM isotype. Macroglobulins raise plasma viscosity and are associated with monoclonal gammopathies of undetermined significance, Also spelled macroglobulinaemia. Also called Waldenström's macroglobulinemia. See also multiple myeloma.
enlarge picture
Macroglobulinemia

mac·ro·glob·u·lin·e·mi·a

(mak'rō-glob'yū-li-nē'mē-ă)
Increased levels of macroglobulins in the blood.
Synonym(s): macroglobulinaemia.

macroglobulinemia

increased levels of immunoglobulin M in the blood.

Waldenström's macroglobulinemia
a monoclonal gammopathy in which there are increased levels of IgM as a result of leukemia affecting IgM-producing B lymphocytes.
References in periodicals archive ?
MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia.
Using the index terms malabsorption, postgastrectomy, chronic pancreatitis, pancreatic cancer, cystic fibrosis, gallstones, cholangitis, celiac disease, tropical sprue, Crohn's disease intestinal lymphangiectasia, macroglobulinemia and iron deficiency anemia the MEDLINE and EMBASE databases were searched.
Characteristics of 4 case-patients with disseminated Talaromyces marneffei infection after targeted therapies * Characteristic Case-patient 1 Age, y/sex 56/M Concurrent conditions Waldenstrom macroglobulinemia, idiopathic thrombocytopenic purpura, primary biliary cirrhosis Targeted therapy Rituximab Action of therapy mAb against CD20 Time interval, mot 18 Cumulative dose before 700 mg/dose iv T.
Bone marrow cancers such as multiple myeloma and Waldenstrom macroglobulinemia often cause a person to have too much of one type of immunoglobulin in the blood.
Glycoproteins in serum from patients with myeloma, macroglobulinemia and related conditions.
m's macroglobulinemia, which is treated with plasmapheresis and chemotherapy.
ARGX-110 is currently being evaluated across a range of hematological and solid tumors in a Phase 1b study in Europe and will be developed in a Phase 2 trial in sponsorship with the Leukemia & Lymphoma Society (LLS) for the rare lymphoma Waldenstrom's macroglobulinemia.
Coyle, Frank and Leonard (1963): Macroglobulinemia with its effect upon the eye.
La inhibicion del proteosoma ha resultado un mecanismo efectivo (8,9) no solo en el tratamiento del mieloma multiple sino en otras discrasias hematologicas como macroglobulinemia de Waldenstrom, linfomas no Hodgkin de bajo grado y amiloidosis primaria (10).
In 2007, I was diagnosed with a rare and incurable form of blood cancer called Waldenstrom's Macroglobulinemia which affects roughly 1,500 in the U.
In addition, SLE and SS are also associated with some plasma cell dyscrasias, such as monoclonal gammopathy of undetermined significance, macroglobulinemia, and amyloidosis; however, multiple myeloma (MM) as a lymphoproliferative neoplasm and plasma cell dyscrasia are not nearly as common.
We did a review of major clinical trials of bortezomib in patients with multiple myeloma, Waldenstrom's macroglobulinemia and plasma cell leukaemia (Table 2) to investigate the incidence of congestive cardiac failure reported after administration of bortezomib.